Erik A. Imel

Erik A. Imel conducts clinical medical research focused on rare disorders of phosphate and mineral metabolism, especially X-linked hypophosphatemia (XLH), a genetic condition that affects bone growth and strength. Much of the work evaluates how treatments such as burosumab and other therapies affect outcomes in children and adults, often using real-world patient data and clinical practice guidelines. Related work extends to conditions like osteogenesis imperfecta (brittle bone disease) and congenital adrenal hyperplasia.

Publication activity has remained steady and generally high over the past decade, averaging about 13-14 papers per year in the last five years.

Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026